All Cardiovascular disease articles
-
eLearning moduleDeep dive on SGLT2 inhibitors with a focus on Jardiance® (empagliflozin)
This eLearning module has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice and Guidelines Learning. Products are discussed.
View Jardiance® (empagliflozin) prescribing and adverse event reporting information for Great Britain or Northern Ireland
PC-GB-104397 April 2021 -
Supplement
Improving outcomes in the management of patients with chronic coronary syndrome and stable anginal chest pain for the acute and general physician
Information intended for UK healthcare professionals only.
This promotional supplement has been commissioned and funded by A. Menarini Farmaceutica Internazionale SRL and developed in partnership with Guidelines in Practice.
View Ranexa (ranolazine) prescribing information and adverse event reporting information here
PP-RA-UK-0627
Date of preparation: July 2021 -
Medicines appraisal cards
NICE Technology Appraisal 694: Bempedoic acid▼ with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK.
View Bempedoic acid (Nilemdo®▼) & Bempedoic acid and ezetimibe (Nustendi®▼) prescribing and adverse event reporting information
BEM/21/0374 May 2021 -
Implementing guidelines
Diabetes in chronic kidney disease requires practical, evidence-based care
Dr Pam Brown and Dr Colin Kenny discuss recommendations from a new international guideline on diabetes management in patients with chronic kidney disease
-
Implementing guidelines
Diabetes: adapt management to account for cardiovascular disease risk
Professor Peter J Grant and Professor Francesco Cosentino highlight the key recommendations from the 2019 ESC/EASD guideline on diabetes, pre-diabetes, and CVD
-
Test and reflect
Patient scenarios: diabetes and cardiovascular risk
The following scenarios are fictitious but similar to those experienced by real patients and are designed to help you reflect on what you have learnt after reading the article. They could also be used for group discussion in an education or practice meeting. There are no right or wrong answers ...
-
Test and reflect
SIGN guideline on pharmacological management of type 2 diabetes
This CPD activity consists of 5 multiple-choice questions (MCQs) designed to test your knowledge on SIGN guideline recommendations on managing type 2 diabetes—you will then be prompted to reflect on your learning.
-
Implementing guidelines
Cardiac rehabilitation should be individualised to meet patient needs
Dr Alan Begg explores updated SIGN recommendations on cardiac rehabilitation and strategies that encourage patient engagement in lifestyle risk factor management, psychosocial wellbeing, and behaviour change.
-
Implementing guidelines
Estimating cardiovascular risk is key to preventing disease
Dr Alan Begg summarises new SIGN guidance and explains why lifestyle change is an essential aspect of cardiovascular risk reduction
-
Top tips
Top tips: venous thromboembolism
Dr Alan Begg discusses the diagnosis, assessment, and management of thromboembolic disease in primary care
-
News
SIGN releases updated guidance on cardiovascular disease
The Scottish Intercollegiate Guidelines Network (SIGN) has published SIGN 149 Risk estimation and the prevention of cardiovascular disease and SIGN 150 Cardiac rehabilitation.
-
NICE quality standard article
Primary care needs a strategy to help identify CVD risk
Dr Ivan Benett shows how NICE has prioritised guidance on cardiovascular risk assessment and lipid modification into a quality standard to improve patient outcomes and experience
-
Personal view
Should everyone with a 10% risk of CVD take a statin?
Dr Terry McCormack revisits recent controversies about NICE guidance on statins and offers patient scenarios illustrating his own approach in clinical practice
-
Implementing guidelines
JBS3 guideline focuses on both short-term and lifetime risk of CVD
Professor John Deanfield explains how the JBS3 approach to CVD risk reduction encompasses the whole population rather than just those individuals at high short-term risk
-
Personal view
Lifetime CVD risk calculator invites earlier interventions
Dr Alan Begg summarises key aspects of JBS3 that are relevant to primary care and considers some implications for clinical practice
-
GMS contract
Primary prevention of CVD is given greater prominence in QOF
Dr Alan Begg explains how the QOF indicators for 2011/2012 have been updated to improve identification of cardiovascular risk in people with serious mental illness
-
Implementing guidelines
Controlling triglyceride levels can reduce risk of CVD and pancreatitis
Dr Honor Merriman discusses how a recently published consensus guideline should help healthcare professionals to assess and manage patients with hypertriglyceridaemia
-
GMS contract
Risk assessment can help in the primary prevention of CVD
Dr Alan Begg explains how QOF-driven identification of patients with hypertension, along with NICE guidance and screening programmes, can help to reduce CVD prevalence
-
Personal view
Lowering cholesterol levels reduces CVD mortality
Dr Alan Begg discusses how the NICE technology appraisal on ezetimibe will make it easier for GPs to reach QOF cholesterol targets
-
Good practice initiative
Patients benefit from a simple CVD risk recording project
Dr Zaid Albrefkany’s winning team in the 2007 Guidelines in Practice Cardiovascular Disease Award set up an audit of CVD risk recording, which led to targeted treatment of high-risk patients
